CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Beclomethasone +2 moredrug
Likely dose
Beclomethasone 84 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05970731
NCT05970731Phase 2Completed
CompareCT.gov

Directed Topical Drug Delivery for Treatment for PASC Hyposmia

Duke University·interventional·Posted Aug 1, 2023·Updated Mar 19, 2026

In Brief

A Phase 2 clinical trial evaluating Beclomethasone, Placebo, and 1 other intervention for Post Acute Sequelae Covid-19 Hyposmia. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Acute Sequelae Covid-19 Hyposmia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 1, 2023
Enrollment StartSep 5, 2023
Primary CompletionOct 7, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.9 years ago

Interventions

Beclomethasonedrug

84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.

Placeboother

Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.

Microspongedevice

Drug delivery using chitosan-based biocompatible microsponge